Richter transformation-is there light at the end of this tunnel?

This article reviews recent therapeutic developments, focusing on inhibitors of BTK, BCL2, the PD1-PDL1 axis, and T-cell-activating/engaging therapies. Herein, I discuss the importance of randomized clinical trials in a disease where small single-arm studies dominate; industry engagement, including the role of registrational studies; and the need to integrate prospectively planned correlative biological studies embedded within future clinical trials to help discover which patient benefits most from each class or combination of novel targets.PMID:38066897 | PMC:PMC10727096 | DOI:10.1182/hematology.2023000442
Source: Hematology ASH Education Program - Category: Hematology Authors: Source Type: research